1) Total Therapy trials at St. Jude raised cure rates for childhood leukemia from <10% to >95% by applying all active drugs upfront rather than reserving agents for relapse. 2) The first myeloma tandem transplant trial (Total Therapy 1) enrolled 231 patients, and at 10 years 33% were still alive and 15% had never relapsed. 3) Total Therapy 3 for multiple myeloma incorporated Velcade into induction and consolidation therapies before and after transplants, achieving faster and deeper responses compared to Total Therapy 2.